SRR8943021
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.520
- ALLOGRAFT_REJECTION+0.440
- IL6_JAK_STAT3_SIGNALING+0.350
- TGF_BETA_SIGNALING+0.340
- HYPOXIA+0.290
- OXIDATIVE_PHOSPHORYLATION+0.290
- P53_PATHWAY+0.270
- COMPLEMENT+0.260
- ANGIOGENESIS+0.250
Top 10 suppressed
- E2F_TARGETS-0.470
- G2M_CHECKPOINT-0.380
- MYC_TARGETS_V2-0.280
- MITOTIC_SPINDLE-0.240
- SPERMATOGENESIS-0.190
- UV_RESPONSE_DN-0.110
- MYC_TARGETS_V1-0.100
- BILE_ACID_METABOLISM-0.070
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.060
- PEROXISOME-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2021 | Med | Medulloblastoma | 0.859 |
| 2 | C3L-02219 | — | cohortA1 | 0.849 |
| 3 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.837 |
| 4 | BS_3G3KWY18 | low-grade glioma | — | 0.829 |
| 5 | BS_YA8RBGD8 | low-grade glioma | — | 0.823 |
| 6 | BS_VW85Q4XJ | low-grade glioma | — | 0.820 |
| 7 | BS_55JW3HFM | Ganglioglioma | — | 0.819 |
| 8 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.819 |
| 9 | DRR168598 | — | — | 0.818 |
| 10 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |